Taxol

(paclitaxel)

ApprovedSmall molecule

Paclitaxel is a chemotherapy drug used to treat various cancers including breast cancer, ovarian cancer, and lung cancer by stopping cancer cells from dividing and growing.[2] Taxol is currently approved and in use across 204 indications[4].[1]

Taxol is one of 1625 small molecule programs targeting Esophageal Cancer. It is currently in Approved.

204

Indications

2,256

Total Trials

Active Trials

1,624

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Esophageal CancerCompleted

Non-Small Cell Lung CancerCompleted

Uterine CancerTerminated

Esophageal Squamous Cell CarcinomaActive, not recruiting

Endometrial CancerUnknown status

Anatomic Stage IV Breast Cancer AJCC V8Recruiting

Advanced Solid TumorsTerminated

Oropharyngeal CancerRecruiting

CarboplatinUnknown status

PembrolizumabRecruiting

Esophageal CancerPhase 3

Completed

Non-Small Cell Lung CancerPhase 3

Completed

Uterine CancerPhase 3

Terminated

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Endometrial CancerPhase 3

Unknown status

Anatomic Stage IV Breast Cancer AJCC V8Phase 2

Recruiting

Advanced Solid TumorsPhase 2

Terminated

Oropharyngeal CancerPhase 2

Recruiting

CarboplatinPhase 3

Unknown status

PembrolizumabPhase 2

Recruiting

Showing 10 of 203 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Adenocard

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Rilvegostomig

AstraZeneca

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cervical Cancer

NCT03534713

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Phase 3Recruiting

Ovarian Cancer

NCT06394492

Q2 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06531447

Q2 2028

Phase 3Recruiting

Small Cell Lung Cancer

NCT06954246

Phase 3Active, not recruiting

Breast Cancer

NCT05840211

Clinical

Trials by Indication[1]

Breast Cancer46 trials

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00915603·113 enrolled

TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen

Withdrawn·JJules Bordet Institute·Phase 2·NCT02053597

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04538742·245 enrolled

Show 43 more trials

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated· Amgen logo

Amgen·Phase 2·NCT00356681·282 enrolled

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Completed·UUniversity of Chicago·Phase 1·NCT00724386·26 enrolled

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Terminated·UUniversity of Washington·Phase 1/2·NCT00041470·38 enrolled

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Completed· Pfizer logo

Pfizer·Phase 3·NCT01989676·707 enrolled

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03609047·366 enrolled

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting·TThe National Center of Oncology, Azerbaijan·Phase 2·NCT06531447·200 enrolled

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00431080·478 enrolled

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT00679029·15 enrolled

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

Completed·QQueen Mary University of London·Phase 2·NCT02423603·71 enrolled

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191672·120 enrolled

Central Catheters Used for Chemotherapy in Women With Breast Cancer

Completed·UUnknown Sponsor·N/A·NCT04324346·250 enrolled

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT00645177·10 enrolled

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00068757·23 enrolled

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Completed· Roche logo

Roche·Phase 1·NCT01918254·66 enrolled

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00455533·384 enrolled

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00773695·150 enrolled

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00270491·130 enrolled

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 1/2·NCT02628132·22 enrolled

"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer

Completed·NNational Center of Oncology, Armenia·Phase 2·NCT03072992·150 enrolled

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00467012·122 enrolled

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Terminated·MMontefiore Medical Center·Phase 1·NCT02824575·28 enrolled

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00373256·488 enrolled

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Withdrawn·UUniversity of Kansas·Phase 2·NCT01163929

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00002826·36 enrolled

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer

Completed·—·Phase 2·NCT02263495·118 enrolled

MEtronomic TrEatment Option in Advanced bReast cAncer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02954055·140 enrolled

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05189067·190 enrolled

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Terminated·PPamela Munster·Phase 1·NCT02358200·23 enrolled

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01827163·20 enrolled

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Completed·—·Phase 3·NCT00146549·250 enrolled

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Not yet recruiting·FFudan University·Phase 3·NCT05841381·876 enrolled

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Completed·NNektar Therapeutics·Phase 3·NCT02915744·178 enrolled

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129922·1,289 enrolled

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02301988·151 enrolled

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Completed·—·Phase 2·NCT02789657·32 enrolled

R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00028873·35 enrolled

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02163694·513 enrolled

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Unknown status·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00005581·1,000 enrolled

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052351

Non-Small Cell Lung Cancer23 trials

Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00002519·6 enrolled

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT01493843·501 enrolled

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03850444·262 enrolled

Show 20 more trials

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004126·38 enrolled

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Completed· Eisai logo

Eisai·Phase 1·NCT00832819·28 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Completed·EECOG-ACRIN Cancer Research Group··NCT00900172·180 enrolled

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05487391·632 enrolled

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT03871153·7 enrolled

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00547443

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT02492867·49 enrolled

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00003159·600 enrolled

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193362·200 enrolled

ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed· Sanofi logo

Sanofi·Phase 2·NCT00071188

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT02581943·43 enrolled

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 3·NCT03117049·550 enrolled

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT02412371·48 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03875092·125 enrolled

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003313·243 enrolled

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

Ovarian Cancer15 trials

Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

Unknown status· GSK logo

GSK·Phase 2·NCT00003733·40 enrolled

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04000295·280 enrolled

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Withdrawn·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 3·NCT03806049

Show 12 more trials

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Completed·VValerio Therapeutics·Phase 1/2·NCT00421889·80 enrolled

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Completed· Roche logo

Roche··NCT02393898·76 enrolled

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00660842·800 enrolled

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

Unknown status·CCytran·Phase 2·NCT00017303

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00326456·820 enrolled

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Completed·UUniversity College, London·Phase 2/3·NCT01196741·107 enrolled

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Completed·DDavid O'Malley·Phase 1·NCT01220154·9 enrolled

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00189566·165 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Fallopian Tube Cancer8 trials

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Unknown status·GGOG Foundation·Phase 3·NCT00108745·1,157 enrolled

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Unknown status·GGynecologic Oncology Group··NCT01366183·290 enrolled

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT01402271·88 enrolled

Show 5 more trials

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191646·919 enrolled

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01167712·692 enrolled

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Completed·IImmunoGen, Inc.·Phase 3·NCT02631876·366 enrolled

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Terminated·UUniversity Health Network, Toronto·Phase 1/2·NCT01083537·1 enrolled

Esophageal Squamous Cell Carcinoma4 trials

Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Completed·CChinese Academy of Medical Sciences·Phase 1/2·NCT02446574·33 enrolled

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Completed· Novartis logo

Novartis·Phase 1·NCT01822613·48 enrolled

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03719924·106 enrolled

Show 1 more trial

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma

Completed·SShandong Cancer Hospital and Institute·Phase 2·NCT00815308·55 enrolled

66 more indications

Esophageal Cancer4 trials

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00344552·53 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00021320·21 enrolled

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Terminated·—·Phase 2·NCT02392377·1 enrolled

Show 1 more trial

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Unknown status·LLisette Nixon·Phase 2/3·NCT02741856·584 enrolled

Endometrial Cancer4 trials

Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00052312·141 enrolled

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Unknown status·KKorean Gynecologic Oncology Group·Phase 2·NCT00373620·50 enrolled

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Unknown status·GGynecologic Oncology Group·Phase 2/3·NCT02065687·469 enrolled

Show 1 more trial

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00003691·240 enrolled

Lung Cancer4 trials

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00147537·282 enrolled

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Terminated·CCTI BioPharma·Phase 3·NCT00269828·600 enrolled

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020007

Show 1 more trial

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Completed·CCellectar Biosciences, Inc.·Phase 3·NCT00347412·903 enrolled

Squamous Cell Carcinoma3 trials

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Recruiting·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 2·NCT06856213·65 enrolled

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Completed·OOncolytics Biotech·Phase 2·NCT00998192·32 enrolled

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00083057·30 enrolled

Cervical Cancer3 trials

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Withdrawn·SSWOG Cancer Research Network·Phase 3·NCT00057928

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT03534713·310 enrolled

Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer

Unknown status·KKorean Gynecologic Oncology Group·Phase 2·NCT01487226·69 enrolled

Small Cell Lung Cancer3 trials

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06954246·450 enrolled

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Completed·HHoosier Cancer Research Network·Phase 2·NCT00317200·34 enrolled

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04672928·20 enrolled

Lymphoma3 trials

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1/2·NCT00004916

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Completed·FFox Chase Cancer Center·Phase 1·NCT00005021·17 enrolled

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038545·25 enrolled

Primary Peritoneal Cancer3 trials

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Completed·—·Phase 2·NCT00520013·60 enrolled

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00005026

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Terminated·GGynecologic Oncology Group·Phase 2·NCT00084448

Paclitaxel3 trials

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT03264547·446 enrolled

Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001450·58 enrolled

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Completed·—·Phase 2·NCT01853748·512 enrolled

Advanced Urothelial Cancer3 trials

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00350025·41 enrolled

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02256436·542 enrolled

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02033993·199 enrolled

Stage IV Ovarian Epithelial Cancer3 trials

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Completed·AAGO Study Group·Phase 3·NCT00006454

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer

Unknown status·RRussian Academy of Medical Sciences·Phase 2·NCT00964626·60 enrolled

Advanced Cancer3 trials

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003376·330 enrolled

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00005644

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·NNYU Langone Health·Phase 1/2·NCT00004105

Germ Cell Tumor3 trials

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00072215·1 enrolled

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Completed·IInstitut Claudius Regaud·Phase 2·NCT00864318·101 enrolled

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Recruiting·BBeihua Kong·Phase 3·NCT02429687·129 enrolled

Cancer of the Esophagus2 trials

Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 1/2·NCT00008047

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00002984·26 enrolled

Gastric Cancer2 trials

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00003298·39 enrolled

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Unknown status·SSeoul National University Bundang Hospital·Phase 1/2·NCT04526470·55 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00848718·77 enrolled

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003742

Melanoma2 trials

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00110019·823 enrolled

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Completed·SSynta Pharmaceuticals Corp.·Phase 1/2·NCT00084214·103 enrolled

Gastroesophageal Junction Cancer2 trials

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02178956·714 enrolled

Radiation Therapy2 trials

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix

Completed·GGynecologic Oncology Group·Phase 1·NCT00003377·29 enrolled

Ovarian Carcinoma2 trials

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059787·56 enrolled

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Unknown status·NNovoCure GmbH·Phase 1/2·NCT02244502·31 enrolled

Adenocarcinoma2 trials

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07284134·560 enrolled

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Active, not recruiting·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT02509286·438 enrolled

Neoadjuvant Chemotherapy1 trial

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05316376·78 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT03019588·94 enrolled

Neurotoxicity1 trial

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00517621·100 enrolled

Triple-Negative Breast Cancer1 trial

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03348098·20 enrolled

Peripheral Arterial Disease1 trial

Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease

Completed·LLahey Clinic··NCT04647643·8,000 enrolled

Cervical Carcinoma1 trial

Indirect Comparison Topotecan Cervical Carcinoma

Completed· GSK logo

GSK··NCT01345279·1 enrolled

Advanced Head and Neck Cancer1 trial

Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003592·230 enrolled

Recurrent or Refractory Solid Tumors1 trial

Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·SState University of New York - Upstate Medical University·Phase 1·NCT00003555·20 enrolled

First-line1 trial

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled

Refractory or Recurrent Solid Tumor1 trial

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003004·73 enrolled

Cisplatin1 trial

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Completed·WWomen's Cancer Care Associates, LLC·Phase 3·NCT02501954·48 enrolled

Ovarian Epithelial Cancer1 trial

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

Chemotherapy1 trial

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Recruiting·FFudan University·Phase 1/2·NCT06494943·27 enrolled

Patients With Solid Tumors1 trial

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Completed·RRoswell Park Cancer Institute··NCT00003569·2 enrolled

Advanced Malignancies1 trial

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT01325441·565 enrolled

Esophageal Carcinoma1 trial

Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02858206·120 enrolled

Metastatic Melanoma1 trial

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 3·NCT01006252·336 enrolled

Gastric Adenocarcinoma1 trial

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

Completed·YYonsei University·Phase 1/2·NCT02615730·42 enrolled

Metastatic Urothelial Cancer1 trial

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Completed· Astellas logo

Astellas·Phase 3·NCT03474107·608 enrolled

Kidney Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Solid Tumor1 trial

A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor

Completed·SSeoul National University Hospital·Phase 1·NCT04046016·2 enrolled

Metastatic Head and Neck Cancer1 trial

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Terminated· Novartis logo

Novartis·Phase 2·NCT01852292·157 enrolled

Cancer of Unknown Primary1 trial

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Unknown status·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00003558·140 enrolled

Penile Carcinoma1 trial

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Terminated·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT02279576·4 enrolled

Neoadjuvant1 trial

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Completed· Novartis logo

Novartis·Phase 3·NCT00553358·455 enrolled

Solid Tumors1 trial

LDE225 and Paclitaxel in Solid Tumors

Completed·SSwiss Cancer Institute·Phase 1·NCT01954355·30 enrolled

Bladder Cancer1 trial

Paclitaxel in Treating Patients With Early-Stage Bladder Cancer

Completed·—·Phase 1/2·NCT00002917

Recurrent Head and Neck Cancer1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 1·NCT00004097

Abemaciclib1 trial

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Completed·MMedSIR·Phase 2·NCT04603183·162 enrolled

Advanced Solid Cancer1 trial

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00535119·107 enrolled

Metastatic Prostate Cancer1 trial

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003614

Solid Cancers1 trial

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT05403554·70 enrolled

Pembrolizumab1 trial

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting·NNETRIS Pharma·Phase 1/2·NCT04652076·240 enrolled

Prostate Cancer1 trial

Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·NNYU Langone Health·Phase 1·NCT00005048

Patients With Advanced Solid Tumors1 trial

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01276496·13 enrolled

Carboplatin1 trial

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00343291·121 enrolled

Multiple Myeloma1 trial

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Endometrial Carcinoma1 trial

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04865289·130 enrolled

Cancer of the Head and Neck1 trial

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00004865

Metastatic Renal Cell Cancer1 trial

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00077129·22 enrolled

Primary Peritoneal Cavity Cancer1 trial

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·—·Phase 2/3·NCT00075712·150 enrolled

Trial1 trial

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed· Astellas logo

Astellas·Phase 2·NCT02057380·13 enrolled

Metastatic Solid Tumors1 trial

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01938846·90 enrolled

Metastatic Cancer1 trial

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00016874

Unspecified2 trials

Capivasertib China PK Study

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04742036·16 enrolled

NSABP Biospecimen Discovery Project

Unknown status·NNSABP Foundation Inc··NCT01850628·50 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 29, 1992

TAXOL

NDA NDA020262

Jan 7, 2005

ABRAXANE

NDA NDA021660

Jul 27, 2022

PACLITAXEL

NDA NDA211875

May 11, 2023

PACLITAXEL

NDA NDA216338

Sources

References

[1]
ClinicalTrials.gov — 2256 trial records for paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Taxol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216338). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Taxol. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Patent Landscape[6]

Patent Cliff

Feb 13, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8268348Feb 21, 2026

9101543Feb 21, 2026

7758891Feb 21, 2026

8034375Aug 13, 2026

8268348*PEDAug 21, 2026

9 more patents

9101543*PEDAug 21, 2026

7758891*PEDAug 21, 2026

8034375*PEDFeb 13, 2027

9597409Mar 4, 2032

9393318Mar 4, 2032

9393318*PEDSep 4, 2032

9597409*PEDSep 4, 2032

9511046Jan 12, 2034

9511046*PEDJul 12, 2034